Show simple item record

dc.contributor.authorNeuzil, Jirien_US
dc.contributor.authorDong, Lan-fengen_US
dc.contributor.authorRamanathapuram, Lalithaen_US
dc.contributor.authorHahn, Tobiasen_US
dc.contributor.authorChladova, Miroslavaen_US
dc.contributor.authorWang, Xiufangen_US
dc.contributor.authorZobalova, Renataen_US
dc.contributor.authorProchazka, Lubomiren_US
dc.contributor.authorGold, Mikhalen_US
dc.contributor.authorLambrechts, Ruthen_US
dc.contributor.authorTuranek, Jaroslaven_US
dc.contributor.authorT. Akporiaye, Emmanuelen_US
dc.contributor.authorDyason, Jeffreyen_US
dc.contributor.authorRalph, Stephenen_US
dc.date.accessioned2017-05-03T11:46:08Z
dc.date.available2017-05-03T11:46:08Z
dc.date.issued2007en_US
dc.date.modified2009-09-09T07:16:23Z
dc.identifier.issn00982997en_US
dc.identifier.doi10.1016/j.mam.2007.02.003en_AU
dc.identifier.urihttp://hdl.handle.net/10072/19192
dc.description.abstractMitochondria have recently emerged as new and promising targets for cancer prevention and therapy. One of the reasons for this is that mitochondria are instrumental to many types of cell death and often lie downstream from the initial actions of anti-cancer drugs. Unlike the tumour suppressor gene encoding p53 that is notoriously prone to inactivating mutations but whose function is essential for induction of apoptosis by DNA-targeting agents (such as doxorubicin or 5-fluorouracil), mitochondria present targets that are not so compromised by genetic mutation and whose targeting overcomes problems with mutations of upstream targets such as p53. We have recently proposed a novel class of anti-cancer agents, mitocans that exert their anti-cancer activity by destabilising mitochondria, promoting the selective induction of apoptotic death in tumour cells. In this communication, we review recent findings on mitocans and propose a common basis for their mode of action in inducing apoptosis of cancer cells. We use as an example the analogues of vitamin E that are proving to be cancer cell-specific and may soon be developed into efficient anti-cancer drugs.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherElsevier Ltd.en_US
dc.publisher.placeUnited Kingdomen_US
dc.publisher.urihttp://www.elsevier.com/locate/mamen_AU
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom607en_US
dc.relation.ispartofpageto645en_US
dc.relation.ispartofissue5-6en_US
dc.relation.ispartofjournalMolecular Aspects of Medicineen_US
dc.relation.ispartofvolume28en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchcode320000en_US
dc.titleVitamin E analogues as a novel group of mitocans: anti-cancer agents that act by targeting mitochondriaen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyrightCopyright 2007 Elsevier. Please refer to the journal's website for access to the definitive, published version.en_AU
gro.date.issued2007
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record